Severe asthma evaluation and biologic treatment

Difficult-to-control asthma can reflect inhaler technique, missed doses, exposures or another condition. Severe asthma remains uncontrolled despite optimized high-dose treatment and addressing those factors, or worsens when that treatment is reduced. The specialist reviews diagnosis and these issues before choosing a biologic; frequent symptoms alone do not establish severe asthma.

Bring spirometry, eosinophil and relevant IgE results, inhalers, allergy history and records of oral steroids, attacks and hospital visits. Include the current action plan and prior biologic response. Tell the clinician about infections, vaccinations, pregnancy plans and reaction history. Ask where spirometry or biomarker testing takes place rather than assuming every Nao clinic performs it.

Confirm the exact service at the selected clinic before booking. Evaluation, prescribing, testing, training and administration are separate capabilities. Confirm whether the chosen Nao visit covers evaluation, specialist coordination, prescribing or administration. A first appointment does not guarantee a dose. Authorization, pharmacy delivery, storage, an administration order and the clinic’s capacity must be settled first. Ask about visit, drug, administration and testing costs separately and plan the next review before leaving.

The clinician reviews confirmed severe asthma, prior optimized treatment, attacks, oral-steroid use, age and relevant biomarkers such as eosinophils or IgE. Other conditions, route, dosing interval, safety and access also matter. Product indications differ; for example, Tezspire does not require a specific high eosinophil count, while Exdensur targets the eosinophilic phenotype.

Tezspire’s US severe-asthma indication starts at age 12 and does not require a specific high eosinophil count. Biomarkers can still help the clinician compare options, and insurer rules may require additional documentation. Diagnosis, optimized prior care and asthma control need assessment; a normal count alone does not settle treatment suitability.

A biologic does not treat an acute attack. Follow the rescue plan and seek emergency help for severe or rapidly worsening breathing trouble. Continue prescribed controller inhalers; systemic or inhaled steroids should not be stopped abruptly. Review product-specific allergic-reaction and helminth precautions. A long injection interval does not remove the need for day-to-day asthma care. Track attacks, rescue use, symptoms, sleep, activity and steroid exposure. The treating specialist reassesses response over time and decides whether to continue, switch or adjust other treatment. Results vary and a first dose does not prove success. Confirm missed-dose advice for the actual product; do not self-inject Exdensur or transfer its six-month schedule to another biologic.

Benefit is assessed over time and varies by medicine and patient; a first dose does not guarantee immediate control. The specialist sets a trial and review period and follows attacks, rescue use, symptoms, activity and steroid exposure. Continue the prescribed inhalers and emergency plan. A biologic is maintenance treatment and should not be used to treat an acute attack.

A consultation starts with the clinical review and required records. Treatment or a procedure depends on suitability, the actual order, safety checks, staff, supplies and any authorization; booking does not guarantee a dose or procedure that day. Begin with records, lung-function review and optimization of current care. Choose a biologic only after discussing indication, route and goals. Arrange an order, authorization, dispensing and training or administration. Exdensur is a healthcare-provider-administered 100 mg subcutaneous injection every six months. Other asthma biologics have different schedules, and Cinqair is an IV infusion.

Before treatment starts, confirm the diagnosis, the intended benefit, the exact treatment and who will coordinate ongoing care. Begin with records, lung-function review and optimization of current care. Choose a biologic only after discussing indication, route and goals. Arrange an order, authorization, dispensing and training or administration. Exdensur is a healthcare-provider-administered 100 mg subcutaneous injection every six months. Other asthma biologics have different schedules, and Cinqair is an IV infusion.

Prepare the relevant dated records, current medicine list and your main questions, and confirm any treatment-specific instructions before attending. Bring spirometry, eosinophil and relevant IgE results, inhalers, allergy history and records of oral steroids, attacks and hospital visits. Include the current action plan and prior biologic response. Tell the clinician about infections, vaccinations, pregnancy plans and reaction history. Ask where spirometry or biomarker testing takes place rather than assuming every Nao clinic performs it.

Agree on the next review, how response and safety will be checked, and who to contact for symptoms, missed treatment or a refill problem. Track attacks, rescue use, symptoms, sleep, activity and steroid exposure. The treating specialist reassesses response over time and decides whether to continue, switch or adjust other treatment. Results vary and a first dose does not prove success. Confirm missed-dose advice for the actual product; do not self-inject Exdensur or transfer its six-month schedule to another biologic.

Contact the prescribing team and the insurer promptly, before the next treatment date. Ask for the written reason, authorization dates, missing records and the appeal instructions for your plan. Tell the prescriber when the next dose is due so a treatment gap can be assessed. Do not change the dose or substitute another medicine yourself. An appeal or manufacturer assistance request does not establish approval. Appeal routes and deadlines depend on the plan and the kind of denial; New York’s fully insured plan rules do not cover every type of insurance.

Asthma is a long-term condition of the airways in the lungs. The airways can become inflamed and narrowed, making breathing harder. Symptoms may come and go and can worsen into an attack. Having asthma does not by itself mean it is severe or that a biologic is needed; diagnosis and control should be reviewed first.

There is no single known cause of asthma. Family history, environmental exposures, respiratory infections and other factors can contribute, so genes can influence risk without making asthma inevitable. Causes of developing the condition differ from triggers that worsen existing symptoms, such as pollen, exercise or cold air. Review your history and exposures with the clinician.

Asthma can cause chest tightness, shortness of breath, a wheezing sound or cough, often at night or early morning. Symptoms can come and go or worsen with infections or triggers. Other conditions can feel similar, so symptoms alone do not confirm asthma. Follow your asthma action plan, and seek emergency help for severe breathing trouble or symptoms that do not respond to your rescue treatment.

There is no cure for asthma, but treatment and an asthma action plan can control symptoms. Symptoms can vary over time; feeling well does not by itself establish that asthma has gone. Continue the agreed treatment and review changes with the clinician rather than stopping medicines on your own.

Yes. Asthma often starts in childhood, but some people first develop signs in adulthood. New cough, wheeze or breathlessness needs assessment because other conditions can cause similar symptoms. Discuss exposures at work and home, allergies and family history; lung-function testing can help confirm the diagnosis.

Start with a clinical review of symptoms, timing, triggers and health history. Tests may include spirometry and comparison before and after a bronchodilator; sometimes other lung-function or challenge tests are needed. Wheeze, a symptom checklist or one blood result alone does not settle the diagnosis. Ask which tests and follow-up are appropriate for you.